<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216644</url>
  </required_header>
  <id_info>
    <org_study_id>FLOT4</org_study_id>
    <nct_id>NCT01216644</nct_id>
  </id_info>
  <brief_title>5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer</brief_title>
  <official_title>A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locally advanced resectable adenocarcinoma of the stomach or the&#xD;
      esophagogastreal junction without previous therapy will be treated with one of two&#xD;
      chemotherapy combinations before and after surgery. One half of the patients gets&#xD;
      5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others Epirubicin,&#xD;
      Cisplatin and 5-FU (ECF). Main objective of the study is median overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      714 Patients with locally advanced resectable (T2-4 and/or N+, M0) adenocarcinoma of the&#xD;
      stomach or the esophagogastreal junction without previous therapy will be included in this&#xD;
      study. After randomization patients receive perioperatively 4 cycles FLOT or 3 cycles ECF,&#xD;
      followed by a restaging of the tumour status and surgery. Subsequently another 4 cycles of&#xD;
      FLOT or 3 cycles ECF are applicated. Then a central validation of the pathological remission&#xD;
      rate is scheduled. Primary endpoint is overall survival, secondary endpoints are disease free&#xD;
      survival, perioperative morbidity and mortality, histopathologic regression rate and&#xD;
      R0-resection rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median overall survival</measure>
    <time_frame>2 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>histopathological regression rate</measure>
    <time_frame>6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival (DFS)</measure>
    <time_frame>2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation of pCR and DFS with survival</measure>
    <time_frame>2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Morbidity and Mortality</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0-Resection rate</measure>
    <time_frame>2 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">716</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>2600 mg/m²d1 i.v. every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>200 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m2, d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>50 mg/m2, d1, i.v., every 3 weeks</description>
    <arm_group_label>ECF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>60 mg/m², d1, i.v., every 3 weeks</description>
    <arm_group_label>ECF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>200 mg/m², d1-d21, i.v., every 3 weeks</description>
    <arm_group_label>ECF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. locally advanced (&gt;T1) and/or nodal positive (N+) histologically proven adenocarcinoma&#xD;
             of the esophagogastreal junction (AEG I-III) or the stomach without distant metastases&#xD;
             (M0) and without infiltration of adjacent structures and organs&#xD;
&#xD;
          2. no previous surgical resection&#xD;
&#xD;
          3. no previous cytostatic chemotherapy&#xD;
&#xD;
          4. Age &gt; 18 years (female and male)&#xD;
&#xD;
          5. ECOG ≤ 2&#xD;
&#xD;
          6. surgical resectability&#xD;
&#xD;
          7. Exclusion of peritoneal carcinomatosis (if clinically suspected) via laparoscopy&#xD;
&#xD;
          8. Leucocytes &gt; 3.000/µl&#xD;
&#xD;
          9. Platelets &gt; 100.000/µl&#xD;
&#xD;
         10. Serum creatinin ≤ 1.5x of normal value, or Creatinin-Clearance &gt; 50 ml/min&#xD;
&#xD;
         11. written informed consent.&#xD;
&#xD;
         12. Ejection fraction &gt; 50% in echocardiography before start of therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. distant metastases or infiltration of adjacent structures or organs and all primarily&#xD;
             not resectable stages&#xD;
&#xD;
          2. relapse&#xD;
&#xD;
          3. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin.&#xD;
             Epirubicin and Docetaxel&#xD;
&#xD;
          4. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin,&#xD;
             Cisplatin, Epirubicin or Docetaxel&#xD;
&#xD;
          5. Active CHD, Cardiomyopathy or cardiac insufficiency stage III-IV according to NYHA&#xD;
&#xD;
          6. malignant secondary disease, dated back &lt; 5 years (exception: In-situ-carcinoma of the&#xD;
             cervix uteri, adequately treated skin basal cell carcinoma)&#xD;
&#xD;
          7. severe non-surgical accompanying disease or acute infection&#xD;
&#xD;
          8. peripheral polyneuropathy &gt; NCI Grad II&#xD;
&#xD;
          9. severe liver dysfunction (AST/ALT&gt;3,5xULN, AP&gt;6xULN, Bilirubin&gt;1,5xULN)&#xD;
&#xD;
         10. chronic inflammable gastro-intestinal disease&#xD;
&#xD;
         11. inclusion in another clinical trial&#xD;
&#xD;
         12. pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Krankenhaus Nordwest</investigator_affiliation>
    <investigator_full_name>Prof. Dr. S.E. Al-Batran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>perioperative</keyword>
  <keyword>FLOT</keyword>
  <keyword>ECF</keyword>
  <keyword>pathological complete remission</keyword>
  <keyword>locally advanced resectable adenocarcinoma of the esophagogastric juction or the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

